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There is currently no consensus on the duration of monitoring required
after TAVI. Between october 2009 and november 2013, 371 consecutive
patients underwent transfemoral TAVI in our institution, all performed using
the Edwards SAPIEN-XT prosthesis and local anesthesia.
All the patients were monitored in intensive care unit for at least 24 hours after
TAVI. We excluded 12 Patients implanted with a Corevalve, 14 patients who died
before discharge, and 8 patients who were not discharge d straight home.
The remaining 337 patients were discharged at home, 121 (36%) within
3 days (early discharge group) and 216 (64%) more than 3 days after TAVI
(conventional discharge group).
The primary end point combined death and re-hospitalization at 30 days.
All adverse events were adjudicated according to the Valve Academic
Research Consortium-2.
The incidence of early discharge rose from 0% in 2009 to 53.2% of cases
in 2013. Before (plutôt prior to?) TAVI, patients in the early discharge group
were less symptomatic (NYHA >III: 64.5% vs. 75.5%, p=0.01) and had less
renal failure (creatinine: 102.1±41.0 vs. 113.3±58.9μmol/l, p=0.04), less atrial
fibrillation (33.1% vs. 46.3%, p=0.02), and less previous balloon aortic valvu-
loplasty (11.6% vs. 23.1%, p=0.01) than those in the conventional discharge
group. In contrast, patients in the early discharge group were more likely to
have a pacemaker before TAVI (16.5% vs. 8.3%, p=0.02).
After multivariable analysis, pacemaker before TAVI (OR 0.44; 95% CI
0.19-0.99; p=0.05), previous balloon aortic valvuloplasty (OR 2.26; 95% CI
1.10-4.64; p=0.03), transfusions (OR 9.6; 95% CI 2.36-38.94; p=0.002), and
delta creatinin (OR 0.99; 95% CI 0.98-0.99; p=0.02) were independent predic-
tive factors of early discharge. The primary end-point occurred in 7 (5.8%)
patients in the early discharge group and in 16 (7.1%) patients in the conven-
tional discharge group without significant difference (p=0.60). No patients
died in the early discharge group at 30-day follow-up.
The results of our study suggest that early discharge is feasible and safe
after TAVI using the Edwards-SAPIEN XT prosthesis in selected patients 
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Background: Aortic valve stenosis (AVS) can be complicated by bleeding
associated with acquired type 2A von Willebrand syndrome. The association
of AVS and gastrointestinal bleeding from angiodysplasia is defined as
Heyde's syndrome. We sought to evaluate the impact of TAVI on primary
hemostasis disorders and to assess its effectiveness to treat Heyde's syndrome. 
Methods: We prospectively enrolled 49 consecutive patients with severe
AVS referred to our institution for TAVI. Biological primary hemostasis
parameters were assessed at baseline and one week after the procedure. 
Results: At baseline, a significant link between vWF abnormalities and the
severity of AVS was evidenced: mean aortic transvalvular gradient was nega-
tively correlated with the levels of vWF antigen (vWF: Ag) (r=–0.29, p<0.05),
vWF ristocetin cofactor activity (vWF:RCo) (r=–0.402, p=0.006) and vWF col-
lagen-binding activity (vWF:CB) (r=–0.441, p=0.005). One week after the pro-
cedure, a significant increase of vWF:Ag, vWF:RCo, and vWF:CB was
evidenced in the whole cohort (respectively 3.32 vs 2.29 IU/mL, p<0.001; 2.98
vs 1.86 IU/mL, p<0.001; 3.16 vs 2.16 IU/mL, p<0.001). Patients with pre-TAVI
vWF abnormalities consistent with a type 2A vWF syndrome (ratio vWF:CB/
vWF:Ag <0.7) preferentially improved their vWF function with respect to
patients with a normal ratio (relative increase of vWF:CB of 63.8% vs 3.5%). 
Conclusion: Primary hemostasis parameters involving vWF are improved
after TAVI, especially in patients with preexisting abnormalities consistent
with acquired type 2A von Willebrand syndrome. Moreover, our observations,
although limited to a small single-center study, suggest that Heyde's syndrome
can be cured by TAVI.
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Introduction: systolic pulmonary artery pressure (sPAP) is a well known
predictor of outcome in patients with valvular heart disease. In spite of this
fact, limited data are available regarding the assessment of RV function in
patients with aortic stenosis (AS). 
Aim: of this study is therefore to evaluate the prevalence and the determi-
nants of RV dysfunction in severe AS patients
Methods: 201 patients (mean age:79.7±8.7, male sex 55.5%) with severe
AS underwent 2D echocardiography and speckle tracking echocardiography
(STE) for the evaluation of left ventricular and RV function, aortic valve gra-
dients and sPAP. A tricuspid annular plane systolic excursion (TAPSE)
≤17mm was used to define reduced RV ventricular function. 
Results: RV function was impaired in 48 patients (24%). Patients with
reduced TAPSE had an impaired LV ejection fraction (LVEF) (49.2±15.4 vs
57.9±10.9%, p<0.0001), significantly altered STE parameters (GLS: –10.3
±3.9 vs –13.2±3.5%, GCS: –7.0±3. vs –10.4±4.9%, GRS: 18.7±11.6 vs
28.4±15.6, all p<0.001) and a higher sPAP (48.4±15.8 vs 40.9±12.7 mmHg,
p=0.002) with respecto to patients with a normal RV function. Correlates of a
reduced TAPSE were: LVEF (β=0.35, p<0.0001), LV global longitudinal, cir-
cumferential and radial strain (β=–0.40, β=–0.40, β=0.37 respectively, all
p<0.0001), LV indexed stroke volume (β=0.44, s<0.0001), lnNT-proBNP
(β=–0.51, p<0.0001) and sPAP (β=–0.27, p<0.0001). At Kaplan-Meier sur-
vival curve, a TAPSE ≤17mm was associated with a reduced survival in
patients with AS (Log Rank test, p=0.034).
Conclusions: In patients with severe AS, RV function impairment is fre-
quent and is associated with a poor prognosis. The correlations of TAPSE
highlight the RV-LV interdependence in AS patients. Further studies will
clarify the real and independent prognostic value of RV function in severe AS
patients and test for the RV reverse remodelling after treatment of the AS. 
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Introduction: in patients with aortic stenosis (AS), the occurrence of
adverse outcomes does not always correspond to the classical markers of hae-
modynamic severity. Moreover, the evaluation of outcomes in these patients
is often biased by considering surgery as a censor event at follow-up analysis.
Aim of the present study is therefore to evaluate the determinants of prognosis
in patients with severe AS, independently from the treatment modality (aortic
valve replacement/medical therapy).
Methods: 220 patients (mean age: 79.8±8.6 years, male sex: 119, 54%)
with severe AS (aortic valve surface <1cm2 or <0.6cm2/m2) underwent
standard echocardiography to characterize aortic valve gradients and biventri-
cular function. Hospitalization for cardiac cause, heart failure, overall death,
but not intervention on the aortic valve were considered as major adverse car-
diac events (MACEs). 
Results: after a mean follow-up period of 7.8 months, the predefined MACEs
occurred in 57 patients (26%). At Cox regression analysis, LVESV (HR 1.20,
p=0.0025), age (HR 0.79, p=0.03), female sex (HR 1.43, P=0.05) and a Zva>3.2
mmHg/ml/m2 (HR 3.53, p<0.0001) were the strongest predictors of events.
Conclusions: In patients with severe AS, a ZVa >3.2 mmHg/ml/m2 is the
strongest predictor of prognosis, independently from the treatment modality.
The ventriculo-arterial interplay has thus a fundamental role in AS, defining
the natural history of the disease and suggesting that a careful reduction of LV
afterload could be very useful in the clinical management of these patients.
